Lipocomb synergistic mode of action

Rosuvastatin and Ezetimibe in a dual-mechanism therapy to achieve greater LDL-C reduction than statin monotherapy alone. By targeting cholesterol production and absorption simultaneously, Lipocomb supports more effective lipid management and helps patients achieve recommended cardiovascular risk reduction goals.